Sydnexis, Inc.

Molecular Biosystems, Inc.

Acucela Inc.

Novacardia, Inc.

Sirion Therapeutics, Inc.

Kenneth J Widder

David S Baker

Gregory I Ostrow

Harun Takruri

Jay Lichter

Ashwin M Krishnan

Rolf Lohrmann

Harold B Levene

James L Barnhart

Nathan L Mata

Dung Kevin Hong

Jialun Meng

Leslie D Anderson

Diane M Szaflarski

Peter J Westkaemper

Howard C Dittrich

Elaine Villapando

Scott Thomson

Janeth M Bartlett

Roland Blantz

Gary L Bales

Lauren Otsuki

Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

DO stabilized pharmaceutical formulations

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Ophthalmic composition

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

D2O stabilized pharmaceutical formulations

Do stabilized pharmaceutical formulations

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Kenneth J Widder